First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors

被引：43
|
作者：
Kopetz, S.
Mita, M. M.
Mok, I.
Sankhala, K. K.
Moseley, J.
Sherman, B. M.
Bradley, C. R.
Tolcher, A. W.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA
[3] BiPar Sci, Brisbane, CA USA
[4] S Texas Accelerated Res Therapeut, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.3577
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3577
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma
    Blakeley, J. O.
    Ye, X.
    Grossman, S. A.
    Mikkelsen, T.
    Rosenfeld, M. R.
    Bradley, C. R.
    Eichler, A. F.
    Nabors, L. B.
    Desideri, S.
    Supko, J. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] A phase I trial of veliparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), and topotecan (TPT) in patients with solid tumors.
    Hendrickson, Andrea Elisabeth Wahner
    Menefee, Michael E.
    Hartmann, Lynn C.
    Long, Harry J.
    Northfelt, Donald W.
    Reid, Joel M.
    Boakye-Agyeman, Fleix
    Flatten, Karen S.
    Poirier, Guy G.
    Lensing, Janet
    Erlichman, Charles
    Kaufmann, Scott H.
    Haluska, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Pharmacokinetics of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) Inhibitor, in cerebrospinal fluid (CSF) of a patient with breast cancer with carcinomatous meningitis
    Castro, M.
    Li, L.
    Stallings, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors
    Mahany, J. J., Jr.
    Lewis, N.
    Heath, E. I.
    LoRusso, P. M.
    Mita, M. M.
    Rodon, J.
    Tolcher, A. W.
    Sherman, B. M.
    Bradley, C. R.
    Papadopoulos, K. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
    Plummer, Ruth
    Jones, Christopher
    Middleton, Mark
    Wilson, Richard
    Evans, Jeffrey
    Olsen, Anna
    Curtin, Nicola
    Boddy, Alan
    McHugh, Peter
    Newell, David
    Harris, Adrian
    Johnson, Patrick
    Steinfeldt, Heidi
    Dewji, Raz
    Wang, Diane
    Robson, Lesley
    Calvert, Hilary
    CLINICAL CANCER RESEARCH, 2008, 14 (23) : 7917 - 7923
  • [6] Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
    Jens Samol
    Malcolm Ranson
    Edwina Scott
    Euan Macpherson
    James Carmichael
    Anne Thomas
    James Cassidy
    Investigational New Drugs, 2012, 30 : 1493 - 1500
  • [7] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
    LoRusso, Patricia M.
    Li, Jing
    Burger, Angelika
    Heilbrun, Lance K.
    Sausville, Edward A.
    Boerner, Scott A.
    Smith, Daryn
    Pilat, Mary Jo
    Zhang, Jie
    Tolaney, Sara M.
    Cleary, James M.
    Chen, Alice P.
    Rubinstein, Lawrence
    Boerner, Julie L.
    Bowditch, Adam
    Cai, Dongpo
    Bell, Tracy
    Wolanski, Andrew
    Marrero, Allison M.
    Zhang, Yiping
    Ji, Jiuping
    Ferry-Galow, Katherine
    Kinders, Robert J.
    Parchment, Ralph E.
    Shapiro, Geoffrey I.
    CLINICAL CANCER RESEARCH, 2016, 22 (13) : 3227 - 3237
  • [8] Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
    Samol, Jens
    Ranson, Malcolm
    Scott, Edwina
    Macpherson, Euan
    Carmichael, James
    Thomas, Anne
    Cassidy, James
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1493 - 1500
  • [9] Phase I pharmacolkinetic (PK) and pharmacodynamic (PD) evaluation of an oral small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), Ku in patients (p) with advanced tumours
    de Bono, J. S.
    Fong, P. C.
    Boss, D.
    Spicer, J.
    Roelvink, M.
    Tutt, A.
    Mortimer, P.
    O'Connor, M.
    Schellens, J. H. M.
    Kaye, S. B.
    EJC SUPPLEMENTS, 2006, 4 (12): : 153 - 153
  • [10] Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
    Jones, Philip
    Wilcoxen, Keith
    Rowley, Michael
    Toniatti, Carlo
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (08) : 3302 - 3314
12345